In addition, HER2-low BC was associated with a limited immune response compared to HER2-0 BC, as demonstrated by the gene-expression data in the ER-positive tumors and the tumor infiltrating lymphocytes-score in the ER-negative cohort [47]. This evidence concerns the gene ERBB2 and neoplasm.